SCHEMBL8499615

SCHEMBL8499615

COc1cc2nc(-c3ccccc3)oc(=O)c2cc1OC

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.70
▸ MEN1 O00255 1/20 0.70
▸ KLK7 P49862 6/20 0.68
▸ KLK14 Q9P0G3 6/20 0.68
▸ KLK5 Q9Y337 6/20 0.68
▸ CTSG P08311 4/20 0.68
▸ ALDH1A1 P00352 5/20 0.67
▸ KDM4E B2RXH2 5/20 0.67
▸ HPGD P15428 4/20 0.67
▸ NPC1 O15118 2/20 0.67
▸ CTRC Q99895 2/20 0.65
▸ HSD17B10 Q99714 2/20 0.64
▸ MAPK1 P28482 1/20 0.64
▸ MAPT P10636 2/20 0.62
▸ PTK2B Q14289 1/20 0.62
▸ ELANE P08246 3/20 0.60
▸ LMNA P02545 1/20 0.60
▸ RAB9A P51151 1/20 0.60
▸ SMN1; SMN2 Q16637 1/20 0.60
▸ F2 P00734 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22952908 0.93 KLK7 (0.67) KMT2AMEN1KLK7KLK14KLK5
SCHEMBL915062 0.87 KMT2A (0.64) KMT2AMEN1KLK7KLK14KLK5
SCHEMBL17554019 0.87 KLK7 (0.72) KMT2AMEN1KLK7KLK14KLK5
SCHEMBL914043 0.87 HSD17B10 (0.63) KMT2AMEN1KLK7KLK14KLK5
SCHEMBL914160 0.86 KLK7 (0.60) KMT2AMEN1KLK7KLK14KLK5
SCHEMBL17554063 0.85 F2 (0.62) KMT2AMEN1KLK7KLK14KLK5
SCHEMBL10780103 0.85 ELANE (0.77) KMT2AMEN1ALDH1A1KDM4EHPGD
SCHEMBL17297264 0.84 ALDH1A1 (0.59) KMT2AMEN1KLK7KLK14KLK5
SCHEMBL10781834 0.83 ELANE (0.74) KMT2AMEN1ALDH1A1KDM4EHPGD
SCHEMBL22272031 0.82 MEN1 (1.00) KMT2AMEN1KLK7KLK14KLK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE36256-E ADMINISTERING ARYL-SUBSTITUTED QUINOXALINE DERIVATIVES AS ANTIPROLIFERATIVE, ANTICARCINOGENIC AND ANTITUMOR AGENTS RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) 1999-07-20 — — US disclosed
US-5795889-A INHIBITING CELL GROWTH WITH ENZYME INHIBITORS FOR SKIN DISORDERS RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1998-08-18 — — US disclosed
US-5656643-A QUINOLIN PYRIDINE DERIVATIVES; USEFUL FOR TREATING CANCER, LEKEMIA, PSORIASIS, INFLAMMATORY DISODERS, BONE DISORDERS, ATHEROSCLEROSIS AND RESTENOSIS; CONTROLLS CELLULAR REPRODUCTION RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1997-08-12 — — US disclosed
US-5646153-A INHIBITING ABNORMAL CELL PROLIFERATION RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1997-07-08 — — US disclosed
US-5480883-A Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1996-01-02 — — US disclosed
US-5409930-A Inhibits abnoramal cell proliferation; dimethoxyquinoline/ dimethylquinoline/ quinolineoxide/ and quinoxaline derivatives RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1995-04-25 — — US disclosed
EP-0584222-A4 BIS MONO-AND BICYCLIC ARYL AND HETEROARYL COMPOUNDS WHICH INHIBIT EGF AND/OR PDGF RECEPTOR TYROSINE KINASE RHONE POULENC RORER INT (US) 1994-07-06 — — EP disclosed
EP-0584222-A1 BIS MONO-AND BICYCLIC ARYL AND HETEROARYL COMPOUNDS WHICH INHIBIT EGF AND/OR PDGF RECEPTOR TYROSINE KINASE. RHONE POULENC RORER INT (US) 1994-03-02 — — EP disclosed
WO-1992020642-A1 BIS MONO-AND BICYCLIC ARYL AND HETEROARYL COMPOUNDS WHICH INHIBIT EGF AND/OR PDGF RECEPTOR TYROSINE KINASE RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) 1992-11-26 — — WO disclosed
Send feedback